Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfeilstöcker

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Journal of Clinical Investigation|January 5, 2008
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemiaC Sillaber, M Mayerhofer, A Böhm, et al.
Annals of Hematology|August 29, 2020
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH networkWolfgang Füreder, W R Sperr, S Heibl, et al.
Annals of Hematology|June 9, 2025
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)K Nachtkamp, F Schulz, A Kasprzak, et al.
Leukemia Research|August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)J Kaivers, M Lauseker, B Hildebrandt, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Leukemia|October 1, 2010
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5qM Mallo, J Cervera, J Schanz, et al.
Leukemia|February 28, 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)M G Della Porta, H Tuechler, L Malcovati, et al.
Leukemia|June 30, 2020
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDSA Kuendgen, M Nomdedeu, H Tuechler, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Journal of Clinical Investigation|January 5, 2008
Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemiaC Sillaber, M Mayerhofer, A Böhm, et al.
Annals of Hematology|August 29, 2020
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH networkWolfgang Füreder, W R Sperr, S Heibl, et al.
Annals of Hematology|June 9, 2025
Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS)K Nachtkamp, F Schulz, A Kasprzak, et al.
Leukemia Research|August 4, 2018
The IPSS-R has prognostic impact in untreated patients with MDS del(5q)J Kaivers, M Lauseker, B Hildebrandt, et al.
Leukemia|September 30, 2005
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS)U Germing, B Hildebrandt, M Pfeilstöcker, et al.
Leukemia|June 22, 2013
Monosomal karyotype in MDS: explaining the poor prognosis?J Schanz, H Tüchler, F Solé, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Leukemia|October 1, 2010
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5qM Mallo, J Cervera, J Schanz, et al.
Leukemia|February 28, 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)M G Della Porta, H Tuechler, L Malcovati, et al.
Leukemia|June 30, 2020
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDSA Kuendgen, M Nomdedeu, H Tuechler, et al.
Pageof 3